Biotech RadarJobs updated

COMPANY

Glycomine

glycomine.com ↗ · West Coast

Clinical Phase 3

Keywords: rare disease rare diseases Pmm2-CDG Phosphomannomutase 2 Deficiency GLM101

Profile checked Oct 10, 2026

$115.0MRaised (2 yrs)4Trials (company is sponsor)

Raises and deals from press releases

Raises announced in these releases: $115M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

  1. Trial start Phase 2/Phase 3: A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG source ↗
  2. Raise Private equity round — Series C: $115M (total, as published), announced Apr 16, 2025. Source: company's own press page. source ↗
  3. Raise Series C · $115M source ↗
  4. Trial start Phase 2: Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients source ↗
  5. Trial start Phase 2: 24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG source ↗
  6. Trial start —: Natural History Study Protocol in PMM2-CDG (CDG-Ia) source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $115.0M. Last 2 years.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT06657859Open-Label Extension Study to Assess GLM101 in PMM2-CDG PatientsPhase 2Enrolling by invitationSep 30, 20242029-09 (estimated)
NCT06892288A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDGPhase 2/Phase 3Active, not recruitingJul 9, 2025Aug 5, 2026 (actual)
NCT03173300Natural History Study Protocol in PMM2-CDG (CDG-Ia)Not listedCompletedJan 8, 2018Apr 9, 2026 (actual)
NCT0554921924-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDGPhase 2CompletedNov 29, 2022Nov 4, 2025 (actual)
Feedback